Cargando…

Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients

Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Be...

Descripción completa

Detalles Bibliográficos
Autores principales: Colapietro, Francesca, Angelotti, Giovanni, Masetti, Chiara, Shiffer, Dana, Pugliese, Nicola, De Nicola, Stella, Carella, Francesco, Desai, Antonio, Ormas, Monica, Calatroni, Marta, Omodei, Paolo, Ciccarelli, Michele, Aliberti, Stefano, Reggiani, Francesco, Bartoletti, Michele, Cecconi, Maurizio, Lleo, Ana, Aghemo, Alessio, Voza, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457973/
https://www.ncbi.nlm.nih.gov/pubmed/37632080
http://dx.doi.org/10.3390/v15081738
Descripción
Sumario:Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Between January 2020 and January 2023, among 3847 patients consecutively hospitalized for COVID19, 57 (=UDCA group) were taking UDCA. The UDCA and the control groups (n = 3790) did not differ concerning comorbidities including diabetes mellitus type 2 (15.8% vs. 12.8%) and neoplasia (12.3% vs. 9.4%). Liver diseases and vaccination rate were more common in the UDCA group (14.0% vs. 2.5% and 54.4% vs. 30.2%, respectively). Overall mortality and CPAP treatment were 22.8 % and 15.7% in the UDCA, and 21.3% and 25.9% in the control group. Mortality was similar (p = 0.243), whereas UDCA was associated with a lower rate of CPAP treatment (OR = 0.76, p < 0.05). Treatment with UDCA was not an independent predictor of survival in patients hospitalized for COVID-19.